The clearance expands the use of Symphony, which previously served as a treatment for venous thrombosis, to PE. It delivers a comprehensive solution for treating the full spectrum of venous thromboembolism (VTE) patient needs. PE, a life-threatening condition, occurs when blood clots block an artery in the lungs.

“Symphony introduces a new frontline approach to PE treatment that gives physicians full control over the procedure, allowing them to remove more clot in less time and to provide better care for their patients,” said Doug Boyd, SVP and GM of Imperative Care’s Vascular business. “With this expanded indication, Imperative Care is setting a new standard in PE thrombectomy care for physicians and their patients.”